• REUTERS

  • SHARE

Pfizer Inc. and partner BioNTech SE said Monday two of their experimental coronavirus vaccine candidates received “fast track” status from the U.S. Food and Drug Administration, which is designed to speed up the regulatory review process.

The U.S.-listed shares of the German firm climbed about 15 percent, while Pfizer’s stock rose about 5 percent. The news lifted broader market sentiment as investors cheered signs of progress in COVID-19 vaccine development.

In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.

SUBSCRIBE NOW

PHOTO GALLERY (CLICK TO ENLARGE)